Incidence and characteristics of peripheral neuropathy during oxaliplatin-based chemotherapy for metastatic colon cancer

References

• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26
   PubMed Web of Science ®Google Scholar
• Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: Systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Brit Med J 2000; 321(7260)531–5
   PubMedGoogle Scholar
• Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004; 5: 2159–70
   PubMed Web of Science ®Google Scholar
• Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, Dimopoulos M, et al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: A multicenter, randomized, phase II study. Ann Oncol 2005; 16: 869–77
   PubMedGoogle Scholar
• de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Thomas PK. Peripheral Neuropathy. 3rd ed. Vol 2. Philadelphia: WB Saunders; 1993. p 1310–7.
   Google Scholar
• Kleyweg RP, Van der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 1991; 14: 1103–9
   PubMed Web of Science ®Google Scholar
• Kimura J. Electrodiagnosis in diseases of nerve and muscle, principles and practice. 3rd ed. Oxford: Oxford University Press; 2001. pp. 91–166.
   Google Scholar
• Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T. Total neuropathy score. Validation and reliability study. Neurology 1999; 53: 1660–4
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 1997; 15: 808–15
   PubMed Web of Science ®Google Scholar
• Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004; 22: 4753–61
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, et al. for the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. N Engl J Med 2004; 350: 2343–51
   PubMed Web of Science ®Google Scholar
• Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N, Morel A, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10(12 Pt 1)4055–61
   PubMed Web of Science ®Google Scholar
• von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stick K, Kullmann F, et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 2007; 25: 173–80
   PubMed Web of Science ®Google Scholar
• Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: How and why?. Crit Rev Oncol Hematol 2006; 59: 159–68
   PubMed Web of Science ®Google Scholar
• Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 1994; 35: 304–11
   PubMed Web of Science ®Google Scholar
• Berger T, Malayeri R, Doppelbauer G, Krajnik G, Huber H, Auff E, Pirker P. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997; 33: 1393–9
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, et al. Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 2005; 64: 26–31
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 2006; 67: 2253–5
   PubMed Web of Science ®Google Scholar
• Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol 2002; 15: 633–8
   PubMed Web of Science ®Google Scholar
• Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ. Cisplatin Neurotoxicity: The relationship between dosage, time, and platinum concentration in neurological tissue and morphological evidence of toxicity. J Clin Oncol 1992; 10: 795–803
   PubMed Web of Science ®Google Scholar
• Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002; 249: 9–17
   PubMed Web of Science ®Google Scholar
• Davar G, Maciewicz RJ. Deafferentation pain syndromes. Neurol Clin 1989; 7: 289–304
   PubMedGoogle Scholar
• Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005; 5(Suppl 1)S38–S46
   PubMedGoogle Scholar
• Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85: 2293–7
   PubMed Web of Science ®Google Scholar
• Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C. The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 2000; 406: 25–32
   PubMed Web of Science ®Google Scholar
• Verstappen CC, Heimans JJ, Hoekman K, et al. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs 2003; 63: 1549–63
   PubMed Web of Science ®Google Scholar
• Adelsberger H, Quasthoff S, Grosskreutz J, et al. Alteration of sodium channel inactivation kinetics on rat sural nerve by the chemotherapeutic agent oxaliplatin. Biol Chem 1999; 380S: 123
   Google Scholar
• Goodisman J, Hagrman D, Tacka KA, Souid AK. Analysis of cytotoxicities of platinum compounds. Cancer Chemother Pharmacol 2006; 57: 257–67
   PubMed Web of Science ®Google Scholar
• Windebank AJ. Chemotherapeutic neuropathy. Curr Opin Neurol 1999; 12: 565–71
   PubMed Web of Science ®Google Scholar
• Gibson TB, Ranganathan A, D'Orazio A; American Society of Clinical Oncology. Highlights From: the 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006. Clin Colorectal Cancer 2006;5:398–402.
   Google Scholar